mTOR Signaling Inhibition Modulates Macrophage/Microglia-Mediated Neuroinflammation and Secondary Injury via Regulatory T Cells after Focal Ischemia

Luokun Xie, Fen Sun, Jixian Wang, XiaoOu Mao, Lin Xie, Shao-Hua Yang, Dong-Ming Su, James W. Simpkins, David A. Greenberg and Kunlin Jin

*Published online 14 May 2014*

http://www.jimmunol.org/content/early/2014/05/14/jimmunol.1303492

---

**Supplementary Material**

http://www.jimmunol.org/content/suppl/2014/05/14/jimmunol.1303492.DCSupplemental

---

**Why The JI?**

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

---

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at:

http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at:

http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at:

http://jimmunol.org/alerts

---

*The Journal of Immunology* is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852

Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved.

Print ISSN: 0022-1767 Online ISSN: 1550-6606.
mTOR Signaling Inhibition Modulates Macrophage/Microglia-Mediated Neuroinflammation and Secondary Injury via Regulatory T Cells after Focal Ischemia

Luokun Xie,* Fen Sun,* Jixian Wang,†† XiaoOu Mao,‡ Lin Xie,‡ Shao-Hua Yang,* Dong-Ming Su,* James W. Simpkins,*,‡‡ David A. Greenberg,‡ and Kunlin Jin*†

Signaling by the mammalian target of rapamycin (mTOR) plays an important role in the modulation of both innate and adaptive immune responses. However, the role and underlying mechanism of mTOR signaling in poststroke neuroinflammation are largely unexplored. In this study, we injected rapamycin, a mTOR inhibitor, by the intracerebroventricular route 6 h after focal ischemic stroke in rats. We found that rapamycin significantly reduced lesion volume and improved behavioral deficits. Notably, infiltration of γδ T cells and granulocytes, which are detrimental to the ischemic brain, was profoundly reduced after rapamycin treatment, as was the production of proinflammatory cytokines and chemokines by macrophages and microglia. Rapamycin treatment prevented brain macrophage polarization toward the M1 type. In addition, we also found that rapamycin significantly enhanced anti-inflammatory activity of regulatory T cells (Tregs), which decreased production of proinflammatory cytokines and chemokines by macrophages and microglia. Depletion of Tregs partially elevated macrophage/microglia-induced neuroinflammation after stroke. Our data suggest that rapamycin can attenuate secondary injury and motor deficits after focal ischemia by enhancing the anti-inflammatory activity of Tregs to restrain poststroke neuroinflammation. The Journal of Immunology, 2014, 192: 000–000.

Stroke is the fourth leading cause of death and the leading cause of disability in the United States (1). Despite tremendous progress in understanding the pathophysiology of ischemic stroke, translation of this knowledge into effective therapies has largely failed. Systemic thrombolytic with recombinant i.v. tissue plasminogen activator remains the only treatment proven to improve clinical outcome of patients with acute ischemic stroke (2). However, because of an increased risk of hemorrhage beyond a few hours poststroke, only ~1–2% of stroke patients can benefit from recombinant i.v. tissue plasminogen activator (3, 4).

Molecular and cellular mediators of neuroinflammatory responses play critical roles in the pathophysiology of ischemic stroke, exerting either deleterious effects on the progression of tissue damage or beneficial roles during recovery and repair (5). Therefore, postischemic neuroinflammation may provide a novel therapeutic approach in stroke. However, several therapeutic trials targeting neuroinflammatory response have failed to show clinical benefit (6). The cause remains unknown. However, targeting a single cell type or single molecule may not be an adequate clinical strategy. In addition, the biphasic nature of neuroinflammatory effects, which amplify acute ischemic injury but may contribute to long-term tissue repair, complicates anti-inflammatory approaches to stroke therapy.

Mammalian target of rapamycin (mTOR) is a critical regulator of cell growth and metabolism that integrates a variety of signals under physiological and pathological conditions (7, 8). Rapamycin is a Food and Drug Administration–approved immunosuppressant being used to prevent rejection in organ transplantation. Recent data show that mTOR signaling plays an important role in the modulation of both innate and adaptive immune responses (9). In experimental stroke, rapamycin administration 1 h after focal ischemia ameliorated motor impairment in adult rats (10) and in neonatal rats (11) and improves neuron viability in an in vitro model of stroke (12). However, the mechanisms underlying mTOR-mediated neuroprotection in stroke are unclear. In addition, stroke patients often experience a significant delay between the onset of ischemia and initiation of therapy. So it is important to determine whether rapamycin can protect from ischemic injury when administered at later time points.

In this study, we found that rapamycin administration 6 h after focal ischemia significantly reduced infarct volume and improved motor function after stroke in rats. In addition, γδ T cells and neutrophil infiltration were decreased, regulatory T cell (Treg) function was increased, and proinflammatory activity of macrophages and microglia was reduced in the ischemic hemispheres. Tregs from rapamycin-treated brains effectively inhibited proinflammatory cytokine and chemokine production by macrophages and microglia. Our data suggest that rapamycin attenuates secondary injury and motor deficits after focal ischemia by modulating poststroke neuroinflammation.
Materials and Methods

**Focal cerebral ischemia**

Transient focal cerebral ischemia was induced using the suture occlusion technique, as previously described (13). Briefly, male Sprague-Dawley rats weighing 250–300 g were anesthetized with 4% isoflurane in 70% N2O/30% O2 using a mask. The neck was incised in the midline, the right external carotid artery (ECA) was carefully exposed and dissected, and a 19-mm-long 3-0 monofilament nylon suture was inserted into the ECA into the right internal carotid artery to occlude right middle cerebral artery at its origin. After 90 min, the suture was removed to allow reperfusion, the ECA was ligated, and the wound was closed. Sham-operated rats underwent an identical procedure, except that the suture was not inserted. Rectal temperature was maintained at 37.0 ± 0.5°C using a heating pad and heating lamp. Regional cerebral blood flow was measured by laser-Doppler flowmetry (Instrument) using the probe positioned over the left hemisphere, 1.5 mm posterior and 3.5 mm lateral to the bregma. After reperfusion for various periods, rats were anesthetized and perfused through the heart with 4% paraformaldehyde in PBS (pH 7.4). All animal experiments were carried out in accordance with National Institutes of Health guidelines and with the approval of the Institutional Animal Care and Use Committee.

**Intracerebroventricular administration of rapamycin**

Rats were implanted with an osmotic minipump to the left lateral ventricle 6 h after middle cerebral artery occlusion (MCAO). For neurobehavioral tests and lesion volume measurement, each rat was intracerebroventricularly infused with 0.5 μl of either rapamycin (1 mg/ml; Calbiochem, La Jolla, CA) or vehicle (artificial cerebrospinal fluid) with the pump positioned over the left hemisphere, 1.5 mm posterior and 3.5 mm lateral to the bregma. After reperfusion for various periods, rats were anesthetized and perfused through the heart with 4% paraformaldehyde in PBS (pH 7.4). All animal experiments were carried out in accordance with National Institutes of Health guidelines and with the approval of the Institutional Animal Care and Use Committee.

**Lesion volume measurement**

Rats were sacrificed 4 wk after MCAO. Coronal sections (100 μm; 400 μm apart; 12–16 per rat, 7 rats per group) were stained with crystal violet. Lesion area was measured by a blinded observer, as described previously (14). Lesion volumes were expressed as a percentage of the volume of the cerebral hemispheres.

**Rapamycin administration**

Intracerebroventricular administration of rapamycin was carried out in a total of 18 rats: 6 vehicle-treated rats and 12 rapamycin-treated rats. Each rat received 2.5 mg Ab in PBS by i.p. injection once per day for 2 d prior to infarct size measurement. The Ab used in this study was rapamycin (Calbiochem, La Jolla, CA), which was administered to the left lateral ventricle 6 h after middle cerebral artery occlusion (MCAO). For neurobehavioral tests and lesion volume measurement, each rat was intracerebroventricularly infused with 0.5 μl of either rapamycin (1 mg/ml; Calbiochem, La Jolla, CA) or vehicle (artificial cerebrospinal fluid) with the pump positioned over the left hemisphere, 1.5 mm posterior and 3.5 mm lateral to the bregma. After reperfusion for various periods, rats were anesthetized and perfused through the heart with 4% paraformaldehyde in PBS (pH 7.4). All animal experiments were carried out in accordance with National Institutes of Health guidelines and with the approval of the Institutional Animal Care and Use Committee.

**Flow cytometry analysis and cell sorting**

For immune cell staining, the following anti-Rat Abs were used: Alexa Fluor 647 anti-TCRε (R73), FITC anti-TCRγδ (V65), allophycocyanin-Cy7 anti-CD4 (W3/25), PE anti-CD8 (G161-1.5) (OX-39), PE/Cy7 anti-CD45 (OX-1), PE anti-CD11b/c (OX-4), and FITC anti-RTBi (MHC-II, OX-6) (BioLegend); Alexa Fluor 647 anti-CD163 (ED2; AbD Serotec); biotinylated anti-granulocyte (RP-1; BD Pharmingen); and biotinylated or PE anti-CD3 (eBioG4.18; eBioscience). Stained cells were analyzed on a BD LSR-II flow cytometer. Dead cells and debris were excluded by staining with propidium iodide (eBioscience). For Treg depletion, unbound cells were incubated with FITC-anti-CD5 mAb (HS7; eBioscience) and subject to flow cytometry analysis.

To explore the effect of rapamycin on myeloid cells, anti-granulocyte (CD11b/c−) myeloid cells were isolated from vehicle-treated ischemic brain hemispheres by flow cytometry. TCRγδ+CD45−CD11b/c+ microphages and CD45+CD11b/c− microglia were sorted from vehicle-treated and rapamycin-treated ischemic brain hemispheres by flow cytometry, respectively. All cells were resuspended in supplemented RPMI 1640. Fifty microliters of cell suspension was added into each well of a 96-well Transwell plate (Corning). A total of 1.25 × 10⁵ γδ T cells was seeded into each well of the insert. The cells were cultured at 37°C for 18 h. All cells in the lower wells (not the insert wells) were then incubated in 1 mM EDTA-PBS for 10 min and collected. Cells were incubated with PE anti-CD3 Ab for 15 min on ice. The number of CD3+ cells was enumerated by flow cytometry.

**Depletion of Tregs in vivo**

To deplete Tregs in vivo, anti-rat CD25 mAb (OX-39; AbD Serotec) was used according to previous literature with modifications (17, 18). Briefly, 2.5 mg Ab in PBS was i.p. injected into each rat once per day for 2 d prior to I/R. Peripheral blood was collected through tail vein at indicated time points to determine the efficiency of Treg depletion by flow cytometry analysis. Rats receiving PBS were used as vehicle control.

**Q-RT-PCR**

Total RNAs were reversely transcribed to cDNAs using SuperScript III First-Strand Synthesis System (Invitrogen), according to the manufacturer’s instructions. Q-RT-PCR was performed using Fast SYBR Green Master Mix (Invitrogen) on a 7300 Real-Time PCR System (Invitrogen). Data were analyzed with 7300 system software. Primer sequences for each gene were shown in Table I.

**Western blot**

Western blot was performed using the protocol as previously described (19). The primary Abs were anti-Phospho-4EBP1 (Thr37/46), anti-4EBP1 (Cell Signaling), and anti-actin (Santa Cruz Biotechnology). Membranes were developed with SuperSignal West Dura Substrate (Thermo Scientific), and the OD was analyzed using a Biospectrum 5000 imaging system (Ultra-Violet Products).

**Statistical analyses**

Quantitative data were expressed as mean ± SEM from the indicated number of experiments. Behavioral data were analyzed by two-way
Results

Rapamycin reduces lesion volume and improves motor deficits after MCAO

To assess the role of rapamycin after focal ischemia, rapamycin or vehicle was administered beginning 6 h, which corresponds more closely to the clinical setting, after MCAO for consecutive 7 d, and rats were euthanized 4 wk after MCAO to measure lesion volume (Fig. 1A). As shown in Fig. 1B and 1C, lesion volume was significantly decreased in the rapamycin- compared with vehicle-treated group. Next, we asked whether blocking mTOR signaling could improve the neurologic deficits after MCAO. As shown in Fig. 1D, there was a significant difference in the motor performance as observed in beam balance test, limb placing test, and elevated body swing test between rapamycin- and vehicle-treated groups, consistent with the effect of rapamycin in functional outcome in rats after I/R.

Rapamycin reduces γδ T cell and granulocyte infiltration

Expression of proinflammatory cytokines and chemokines such as TNF-α, IL-1β, CCL2, and CCL3 is induced as early as 1–2 h after ischemia and is increased for up to 2–5 d (20–25). Importantly, the temporal profile of chemokines such as CCL2 and CCL3 is in line with that of leukocyte accumulation in the ischemic brain parenchyma (26). Leukocyte accumulation is the character of inflammation. Previous studies have indicated that leukocyte accumulation, including T cells, B cells, granulocytes, and monocytes, starts on day 1 and peaks on day 3 after onset of ischemia (16, 27). Thus, postischemic neuroinflammation appears to culminate at day 3 after I/R. So we chose this time point to study the neuroinflammation, hoping to observe significant changes and easily isolate recruited leukocytes. To investigate the mechanism by which rapamycin protected from MCAO-induced damage, we first determined whether rapamycin inhibited inflammatory cell infiltration in the ischemic brain. Total immune cells recovered from rapamycin-treated brains 3 d after ischemia were significantly less than those from vehicle-treated brain (Fig. 2A). We then investigated distinct leukocyte populations. Leukocytes were carefully gated based on CD45 expression and their specific surface markers (Supplemental Fig. 1A). In the ipsilateral (ischemic) hemispheres, there was no significant difference in γδ T cell number between rapamycin- and vehicle-treated groups (Fig. 2B), although a trend of decrease in CD4+ T cells occurred. In contrast, infiltration of γδ T cells and granulocytes in the ipsilateral hemisphere was profoundly inhibited in rapamycin-treated rats compared with vehicle-treated rats (Fig. 2C, 2E). Previous study has shown the pivotal role of γδ T cell–derived IL-17 in the progression of postischemic neuroinflammation in mice (16). Thus, we determined IL-17A expression in infiltrated γδ T cells to check whether rapamycin could influence IL-17A expression. To our surprise, neither IL-17A protein nor IL-17A mRNA was significantly elevated in infiltrated γδ T cells, and rapamycin had no significant effect on IL-17A expression in γδ T cells (Fig. 2D, Supplemental Fig. 1B). These data suggest that, unlike mouse MCAO model, IL-17 might not be an important factor for γδ T cell–induced neuroinflammation in rat ischemia.

Rapamycin inhibits production of proinflammatory cytokines and chemokines by macrophages and microglia

The reduction of immune cells in the ipsilateral hemisphere suggests that recruitment of γδ T cells and granulocytes by postischemic neuroinflammation is restrained by rapamycin treatment. Macrophages and microglia play critical roles in the initiation of postischemic neuroinflammation, including recruitment of blood leukocytes. Therefore, we tested macrophage/microglia-mediated inflammation by detecting production of cytokines and chemokines in these cells. The amount of CD45+CD11b+ macrophages and CD45+CD11b+ microglia was significantly increased in ipsilateral hemispheres in comparison with the contralateral side, but rapamycin treatment did not alter their number, suggesting rapamycin has no effect on the accumulation of macrophages and microglia after stroke (Fig. 3A). Q-RT-PCR with specific primers (Table I) revealed that I/R robustly induced expression of in-

![Image](http://www.jimmunol.org/)

**FIGURE 1.** Rapamycin treatment reduced lesion volume and improved motor deficits after MCAO. (A) The scheme of experimental design. (B) Crystal violet–stained coronal brain sections from rapamycin- and vehicle-treated ischemic rats. (C) Volume loss in vehicle- and rapamycin-treated rats (n = 7 per group). (D) Neurobehavioral tests ( sham group: n = 6–7; MCAO group: n = 10–11). Left, Beam-walking test scores, expressed as the mean numbers of forelimb slip steps when traversing an elevated narrow beam; middle, limb-placing test scores, expressed as a score derived from the number of correct limb placements; right, elevated body swing test scores, expressed as a percentage of turns to the contralesional (impaired) side. *p < 0.05 compared with vehicle-treated rats. Rapa, rapamycin; Veh, vehicle.
flamatory cytokines and chemokines in macrophages and microglia in ischemic hemispheres (Supplemental Fig. 2A). Note that induction of IL-23a (p19) and IL-12b (p40) was not as profound as induction of other cytokines (Supplemental Fig. 2A), suggesting that expression of IL-23 might be relatively low in our model. This could explain why we did not observe significant IL-23 expression in microglia in ischemic hemispheres (Supplemental Fig. 2A). Note that demonstrated that rapamycin enhances proinflammatory activity of macrophages (28, 29). Thus, in vivo decrease of proinflammatory mediators in macrophages and microglia is unlikely due to the direct effect of rapamycin. It is more likely that rapamycin acts on other cell types first and, in turn, those affected cell types induce less inflammatory response of macrophages and microglia. Interestingly, rapa-

Table I. Primer sequences for Q-RT-PCR

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primers (Forward and Reverse)</th>
</tr>
</thead>
<tbody>
<tr>
<td>II10</td>
<td>5'-TAACAGCAATGCTTTAGGACAGC-3'</td>
</tr>
<tr>
<td>Tgfb1</td>
<td>5'-GTCAGCTCTGAGAAGAAGC-3'</td>
</tr>
<tr>
<td>Ebi3</td>
<td>5'-TCAGCTTCTGAGAAGAAGC-3'</td>
</tr>
<tr>
<td>Tnfa</td>
<td>5'-TCAGCTTCTGAGAAGAAGC-3'</td>
</tr>
<tr>
<td>Il1b</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Il6</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Il12b</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Il23a</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Il12b</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>IκBα</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Nrp1</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Fgfl2</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Cxcl12</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Ccl2</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Ccl3</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
<tr>
<td>Gapdh</td>
<td>5'-ATGAGGACCACTGAGCAGA-3'</td>
</tr>
</tbody>
</table>

FIGURE 2. Rapamycin treatment reduced inflammatory cell infiltration after MCAO. (A) The number of total immune cells recovered from ischemic brains. (B) αβ T cell number in ischemic brains. (C) γδ T cell number in ischemic brains. Left, Representative contour plots of brain γδ T cells. Right, Statistical analysis of γδ T cell infiltrates. (D) Flow cytometry analysis of IL-17A expression in infiltrated T cells. αβ T, αβ T cells; Ctrl γδ T, γδ T cells in brains of vehicle-treated rats; Rapa γδ T, γδ T cells in brains of rapamycin-treated rats. This is a representative of three independent experiments. (E) Granulocyte number in ischemic brains. Left, Representative contour plots of brain granulocytes. Right, Statistical analysis of granulocyte infiltrates. Numbers in the plots are the frequencies of each population in total recovered immune cells. n = 8 rats per group. **p < 0.01, ***p < 0.001. Contra, contralateral side; Ctrl, vehicle control; Ipsi, ipsilateral side; Rapa, rapamycin treated.

To our surprise, rapamycin strongly increased CXCL2 mRNA level in macrophages and microglia. In addition, rapamycin significantly reduced CCL2 and CCL3 level in macrophages and microglia (Fig. 3B). The reduction of CCL2 and CCL3 levels could be a reason of decreased leukocyte infiltration in the ischemic brains. To test our hypothesis that rapamycin weakens macrophage/microglia-induced chemoattraction of γδ T cells, we performed in vitro migration assay by culturing splenic γδ T cells with postischemic brain macrophages or microglia in the Transwell plates. Both macrophages and microglia effectively induced migration of γδ T cells 18 h after culture. Compared with control groups, macrophages and microglia isolated from rapamycin-treated brains induced less γδ T cell migration, suggesting their ability to recruit γδ T cells is indeed weakened (Fig. 3C).

The changes in cytokine and chemokine expression could be due to direct or indirect effect of rapamycin on macrophages and microglia. To clarify this, we isolated macrophages and microglia from ischemic rat brains without rapamycin injection. These cells were cultured in vitro in the presence or absence of rapamycin for 24 h, and mRNA levels of cytokines and chemokines were tested by Q-RT-PCR. Rapamycin directly enhanced expression of IL-1β, iNOS, CCL3, and IL-23a, but did not affect expression of TNF-α, IL-6, CXCCL2, and IL-12b in macrophages (Supplemental Fig. 2B). In microglia, expression of IL-1β and iNOS was also promoted by rapamycin (Supplemental Fig. 2B). Our data are generally consistent with previous publications that demonstrated that rapamycin enhances proinflammatory activity of macrophages (28, 29). Thus, in vivo decrease of proinflammatory mediators in macrophages and microglia is unlikely due to the direct effect of rapamycin. It is more likely that rapamycin acts on other cell types first and, in turn, those affected cell types induce less inflammatory response of macrophages and microglia. Interestingly, rapa-
mycin directly inhibited CCL2 expression in both macrophages and microglia (Supplemental Fig. 2B), which is consistent with the in vivo data. CCL2 has been shown to be critical for γδ T cell recruitment in other disorders (30, 31). Hence, rapamycin might directly inhibit CCL2 production in macrophages and microglia, so as to reduce γδ T cell accumulation in ischemic brains.

The expression of anti-inflammatory TGF-β1 and IL-10 was not altered in macrophages and microglia (Supplemental Fig. 3A, 3B). Expression of fibroblast growth factor-2 was upregulated in microglia from rapamycin-treated brains, suggesting microglia might promote brain recovery.

Rapamycin treatment favors brain macrophage polarization toward M2 type

Polarization of macrophages between M1 and M2 type is associated with pro- and anti-inflammatory activity, respectively. Above data suggest that polarization of macrophages and microglia might be changed after rapamycin treatment. Our flow cytometry analysis showed that four subpopulations of macrophages—RTIB-negative CD163+, RTIB-high CD163+, RTIB+CD163+, and RTIB-CD163—were present in contralateral hemispheres (Supplemental Fig. 4). According to published M1 and M2 phenotypes (32, 33), we designated them M0, M1, M1/2, and M2, respectively. However, only very few microglia in contralateral hemispheres expressed RTIB or CD163 (Supplemental Fig. 4). In ipsilateral hemispheres, rapamycin treatment increased the frequency and number of M2 macrophages, compared with vehicle control (Fig. 4A, 4B), suggesting rapamycin treatment favors M2 polarization of macrophages. To our surprise, microglia barely expressed RTIB and CD163 in both contralateral and ipsilateral hemispheres (Fig. 4C, Supplemental Fig. 4), suggesting that...
these surface markers are not suitable for distinguishing microglial polarization.

Rapamycin enhances anti-inflammatory activity of Tregs

It has been shown that rapamycin enriched the population of Tregs (34–36). Tregs are able to protect ischemic brain damage (37). So we asked whether rapamycin could alter Treg number and/or activity in ischemic brains. Treg number in rapamycin-treated brains was comparable to that in vehicle-treated brains. However, the proportion of Tregs in total recovered immune cells was significantly increased (Fig. 5A). Tregs in rapamycin-treated brains expressed higher Foxp3 and CD25 (Fig. 5B), suggesting they have higher regulatory activity than Tregs in the vehicle control brains. To determine the anti-inflammatory activity of Tregs, we sorted TCRαβ⁺CD4⁺CD25^{hi} Treg-enriched cells for Q-RT-PCR (Table 1). mRNA levels of IL-10 in Tregs were not significantly changed, whereas mRNA levels of TGF-β1 and Ebi3 were elevated in Tregs in rapamycin-treated brains (Fig. 5C). Thus, rapamycin treatment enhanced Treg anti-inflammatory activity. Q-RT-PCR revealed that infiltrated Tregs expressed similar levels of helios and neuropilin-1 as those in splenic counterparts (Fig. 5D). Splenic Tregs contain mainly natural Tregs (38). Hence, infiltrated Tregs are mainly natural Tregs as well. This result is consistent with our expectation based on the temporal process of immune response, because adaptive immune reaction has not fully engaged on day 3 after Ag exposure.

Tregs in rapamycin-treated brains inhibit proinflammatory activity of macrophages/microglia

Then we tested whether Tregs in rapamycin-treated brains more potently inhibit macrophage/microglia-mediated inflammation. Because rapamycin treatment induced a similar cytokine/chemokine expression change in macrophages and microglia (Fig. 3B), we used macrophage/microglia mixture for the study. Ischemic macrophages/microglia were cocultured with Tregs isolated from ischemic brains. Tregs, which are CD5⁺, were then effectively depleted with magnetic beads (Fig. 6A). Tregs from vehicle-treated brains moderately inhibited cytokine/chemokine expression, except for TNF-α and CCL2, whereas Tregs from rapamycin-treated brains more robustly inhibited almost all cytokines/chemokines in comparison with Tregs from vehicle-treated brains (Fig. 6B). To confirm that rapamycin inhibited mTOR signaling, brain immune cells were isolated to measure mTOR complex 1 activity by Western blot. Ischemic injury significantly upregulated 4EBP1 and phosphorylated 4EBP1. Rapamycin treatment did not alter 4EBP1 protein levels but significantly reduced 4EBP1 phosphorylation (Fig. 6C). Thus, rapamycin downregulated mTOR complex 1 signaling in infiltrating leukocytes.

Depletion of Tregs partially elevates inflammatory response of macrophages/microglia in rapamycin-treated ischemic brains

To further explore whether Tregs are critical for rapamycin-induced alleviation of neuroinflammatory response in macrophages/microglia, i.p. injection of anti-CD25 Ab was applied to deplete peripheral Tregs before MCAO was performed (Fig. 7A). Peripheral blood was drawn to determine the efficiency of Treg depletion. Three days and 5 d after the initial Ab injection, >50% and 60% of CD4⁺Foxp3⁺ Tregs in the blood were depleted, respectively (Fig. 7B). MCAO and rapamycin injection was performed 2 d after the initial Ab injection. On day 3 after MCAO, brain immune cells were evaluated. Consistent with the reduction of peripheral Tregs, infiltrated Tregs in ischemic brains were also decreased by 60% after Ab treatment (Fig. 7C). In comparison with rats receiving rapamycin and PBS, Treg depletion caused a trend of increase in total immune cell number (Fig. 7D). In comparison with control rats (I/R without additional treatment), the total immune cell number after Treg depletion was relatively lower, but it was not statistically significant (Fig. 7D). Treg depletion induced significant increase of γδ T cells and granulocytes in ischemic brains, compared with rats receiving rapamycin and PBS (Fig. 7E). However, their numbers were still less than the amount of γδ T cells and granulocytes in ischemic brains of control rats, suggesting Treg depletion only partially increases the infiltration of γδ T cells and granulocytes. The numbers of infiltrated γδ T cells, macrophages, and microglia were not significantly altered by Treg depletion (Fig. 7E, 7F).

We then tested the cytokine and chemokine production by macrophages/microglia in ischemic brains after Treg depletion. As shown in Fig. 7G, in comparison with administration of rapamycin and PBS, Treg depletion caused significant increases in the mRNA levels of IL-6, iNOS, CCL2, and IL-12b (p40). However, com-
pared with untreated control group, mRNA levels of IL-6 and IL-12b after Treg depletion were still lower. Only iNOS and CCL2 production was relatively close to the control level. There was a trend of increase in the TNF-α mRNA level after Treg depletion, but it was statistically insignificant. Production of IL-1β and CCL3 was almost not changed. Our data suggest Tregs indeed play a role in rapamycin-induced restraint of neuroinflammatory response of macrophages/microglia. However, the effect of Tregs was not as profound as we expected. Some other cellular components might have contributed to the efficacy of rapamycin. Phenotypic polarization of macrophages was not altered after Treg depletion in comparison with vehicle-treated group (Fig. 7H).

**Discussion**

The results presented in this work reveal that rapamycin administration 6 h after focal cerebral ischemia significantly reduces lesion volume and improves motor deficits, implying a longer therapeutic window of opportunity for ischemic stroke treatment. In addition, rapamycin is able to modulate poststroke neuroinflammatory responses by reducing deleterious and enhancing protective actions of immune cells.

Poststroke neuroinflammation plays critical roles in the pathophysiology of ischemic stroke, which is characterized by peripheral leukocyte influx into the cerebral parenchyma, activation of endogenous microglia, and release of proinflammatory mediators (5, 39). These mediators lead to secondary injury of potentially salvageable tissue within the penumbra regions after ischemic stroke. Granulocytes are generally the first leukocyte subtype recruited to the ischemic brain and may potentiate injury by secreting deleterious neuroinflammatory mediators (40). T lymphocytes also influence the ischemic lesion independently of Ag specificity and costimulatory molecules (41), although there are conflicting data (42). The impact of T cell subsets on secondary infarct progression has been disclosed in recent years. γδ T cells have pivotal roles in the evolution of brain infarction and accompanying neurologic deficits (16). In contrast, Tregs prevent secondary infarct growth (37). However, their protective role still needs further confirmation because controversies emerge (43, 44).
In our study, administration of rapamycin profoundly reduced the number of gd T cells in ischemic brains, suggesting rapamycin might protect brains from gd T cell–mediated damage. However, we could not detect either IL-17 protein or IL-17 mRNA in infiltrated gd T cells. It might be possible that rat gd T cells respond differently from their mouse counterparts, using some mediators other than IL-17 to cause the brain damage. It has been shown that gd T cells also express TNF-α during the development of experimental autoimmune encephalomyelitis (45). The cytokine profile of infiltrated gd T cells is still unclear and needs further investigation.

Interestingly, Treg number in rapamycin-treated brains was not significantly altered, but the Treg proportion in brain immune cells was higher. Thus, it is possible that Tregs can function more efficiently to inhibit inflammatory cells in treated brains. TGF-β and IL-10, which can be produced by Tregs, are shown to be neuroprotective (46–48). Our data showed that although IL-10 level was not enhanced in Tregs, the levels of IL-35 and TGF-β in Tregs were significantly increased by rapamycin. Hence, increased Treg anti-inflammatory activity may contribute to alleviating brain damage. However, it remains unclear whether rapamycin directly or indirectly enhances Treg anti-inflammatory activity in ischemic brains. It has been reported that mTOR signaling negatively regulates Treg commitment, expansion, and function, whereas rapamycin increases Treg number and enhances Treg activity both in vitro and in vivo (49–56). The effect of rapamycin on Tregs is
associated with stabilization of Foxp3 (50, 53), which is the Treg master regulator controlling Treg development and function. Indeed, we found higher Foxp3 level in Tregs in rapamycin-treated brains, suggesting the expression/stabilization of Foxp3 is enhanced by rapamycin treatment. CD25 expression was also higher on Tregs after rapamycin treatment, possibly due to direct binding of Foxp3 to the promoter region of IL2ra. The elevated expression of Ebi3, which is the subunit of IL-35, can also be attributed to higher Foxp3 level, because Ebi3 is a downstream target of Foxp3 (57). However, the higher Foxp3 level in rapamycin-treated Tregs does not explain the unchanged IL-10 and increased TGF-β, because there is no convincing proof showing Foxp3 directly regulates expression of these cytokines. Thus, rapamycin might regulate their expression independently of direct effect of Foxp3.

The higher CD25 expression might reflect higher level of IL-2R on the surface of Tregs in rapamycin-treated brains, thus making these Tregs possess higher affinity for IL-2, which induces more IL-10 expression (58–60). However, rapamycin itself might inhibit IL-10 mRNA and protein in Tregs, as in macrophages (9). Hence, the unchanged IL-10 level might reflect a balance between the effects of IL-2/IL-2R signaling and mTOR inhibition. Researchers have observed rapamycin-induced TGF-β production by lymphocytes and infiltrated Tregs in previous studies (61, 62). Hence, rapamycin might directly increase TGF-β production in Tregs through unknown molecular mechanisms. In addition, Tregs might also be modulated by an indirect effect of rapamycin. It has been reported that rapamycin-treated endothelial cells and dendritic cells may promote Treg activity in ischemic brains (63, 64). Hence, rapamycin-treated endothelial or dendritic cells could induce Tregs to produce immunosuppressive cytokines to restrain the inflammation. However, further investigations are in demand to test our hypothesis.

Previous studies have documented the proinflammatory (M1) and anti-inflammatory (M2) macrophages in the postischemic brains (65, 66). Modulation of microglia and macrophage polarization toward the beneficial M2 type would restrain neuroinflammation and favor functional recovery (33). Our work indicated that rapamycin treatment phenotypically inhibited M1 polarization in brain macrophages. Correspondingly, proinflammatory cytokine and chemokine production in macrophages was inhibited. However, M2 type-related anti-inflammatory cytokine production was not increased, suggesting the effects of rapamycin on macrophage polarization are more complicated than expected. It is also possible that phenotypical polarization starts earlier than functional polarization, or restraint of M1 cytokine production is prior to elevation of M2 cytokine production. In microglia, both phenotypical and functional polarization were not as significant as in macrophages, suggesting the effects of rapamycin treatment on microglia could be weak or require longer time. Macrophages and microglia showed similar changes in chemokine levels after rapamycin treatment. The profound elevation of CXCL12 was unexpected but could be involved in the migration of neural stem/progenitor cells to the lesion site. Decreased production of other chemokines could explain reduced infiltration of granulocytes and γδ T cells. However, inhibited inflammatory response of macrophages and microglia cannot be attributed to the direct effect of rapamycin, because both our data and previous research demonstrated that rapamycin induces macrophages polarization toward the proinflammatory M1 type (30). Thus, the inhibited M1 polarization of macrophages and microglia should be mediated by agents other than rapamycin itself. Interestingly, our data show that the functional change in macrophages/microglia is at least partially due to their interaction with Tregs. Tregs isolated from rapamycin-treated brains more potently inhibited proinflammatory cytokine and chemokine production, consistent with their promoted anti-inflammatory activity. So we concluded that, although rapamycin directly induces M1 polarization of macrophages and microglia, it also strongly enhances Treg activity, which in turn restrains the inflammatory response of macrophages and microglia.

To determine whether Treg is a major target of rapamycin, we depleted Tregs with anti-CD25 Ab before stroke and rapamycin injection. Although Treg depletion was successful, it just partially enhanced inflammatory response in rapamycin-treated brains. It appears that Tregs indeed, but limitedly, contributed to rapamycin-induced anti-inflammation effect. Other cell types might also play roles in this process. Note that rapamycin was injected 6 h after I/R, early before the recruitment of peripheral immune cells. We speculated that rapamycin could inhibit the initiation of neuroinflammation when leukocytes are still outside the brain parenchyma. Both damaged/stressed neurons and reactive astrocytes quickly initiate postischemic inflammation, through producing proinflammatory mediators and educating microglia (41, 42, 43, 68). Rapamycin protects neurons after stroke (12, 69) and inhibits reactive astrocytes (70, 71), thus probably preventing the onset of acute neuroinflammation. Hence, the neuroinflammation might have been alleviated even before Tregs entered the brain parenchyma. Increase of neuroinflammation on day 3 after stroke might be the outcome of both restrained initiation and inhibited progression of neuroinflammation. Tregs might be just involved in the progression phase. This could explain why Treg depletion could not completely abolish the effect of rapamycin. However, careful studies, especially on the initiation of neuroinflammation shortly after I/R, will be needed to test our hypothesis in the future.

In our study, we injected rapamycin into the lateral ventricles, hoping that it functions mainly in the ischemic brains. Based on former studies, peripheral administration of rapamycin also shows neuroprotective effect after stroke (10, 69). Rapamycin can cross the blood brain barrier into the brain parenchyma even in the steady state (72). Thus, peripheral administration of rapamycin might inhibit leukocyte activation in the periphery, prevent neuron death, and restrain astrocyte reaction in the brain, exerting similar effects to intracerebroventricular injection. However, peripheral administration might severely interfere with functions of the immune system and other vital organs/tissues, which might not be good for patients. Taken together, our research suggests intraventricular administration of rapamycin after ischemic stroke restrains proinflammatory activity of macrophages and microglia through Tregs. These studies may have implications for novel therapeutic interventions targeting postischemic neuroinflammation in stroke.

Acknowledgments
Flow cytometry cell sorting was performed by Xiangle Sun in the Flow Cytometry and Laser Capture Microdissection Core Facility at University of North Texas Health Science Center.

Disclosures
The authors have no financial conflicts of interest.

References


